EQUIPALAZONE 200 MG/ML SOLUTION FOR INJECTION
Krajina: Írsko
Jazyk: angličtina
Zdroj: HPRA (Health Products Regulatory Authority)
Súhrn charakteristických
(SPC)
20-08-2016
Niektoré dokumenty týkajúce sa tohto produktu nie sú momentálne k dispozícii, môžete poslať požiadavku na náš zákaznícky servis a my vás upozorníme hneď, ako ich dokážeme získať.
Poslať žiadosť.
Poslať žiadosť.
Aktívna zložka:
PHENYLBUTAZONE
Dostupné z:
Dechra Limited
ATC kód:
QM01AA01
INN (Medzinárodný Name):
PHENYLBUTAZONE
Dávkovanie:
200 Mg/Ml
Forma lieku:
Solution for Injection
Typ predpisu:
POM
Terapeutické skupiny:
Equine Non Food
Terapeutické oblasti:
Phenylbutazone
Terapeutické indikácie:
N.S.A.I.D
Stav Autorizácia:
Authorised
Dátum Autorizácia:
2005-10-01
Súhrn charakteristických
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Equipalazone 200 mg/ml Solution for Injection
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Active substances
Phenylbutazone
200
mg/ml
Excipients
Benzyl Alcohol
0.015 ml/ml
For a full list of excipients see section 6.1.
3 PHARMACEUTICAL FORM
Solution for injection.
Clear, colourless to pale yellow solution.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Horses and ponies
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the treatment of musculo-skeletal disorders in horses and ponies where the anti-inflammatory and analgesic
properties of phenylbutazone can offer relief against inflammation, pain and lameness (for example, osteoarthritis
conditions, acute and chronic laminitis, bursitis and carpitis).
4.3 CONTRAINDICATIONS
The therapeutic index of phenylbutazone is low. Do not exceed the stated dose or the duration of treatment.
Do not administer with other non-steroidal anti-inflammatory agents concurrently or within 24 hours of each other.
Do not use in animals suffering from cardiac, hepatic or renal disease; where there is the possibility of gastro-intestinal
ulceration or bleeding; where there is evidence of a blood dyscrasia or of hypersensitivity to the product.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
Discontinue treatment if no response is evident after four to five days treatment.
The clinical effect of phenylbutazone can be evident for at least three days following cessation of administration. This
should be borne in mind when examining horses for soundness.
HEALTH PRODUCTS REGULATORY AUTHORITY
________________________________________________________________________________________________________________________
_Date Printed 05/08/2016_
_CRN 7023797_
_page number: 1_
4.5 SPECIAL PRECAUTIONS FOR USE
(I) SPECIAL PRECAUTION
Prečítajte si celý dokument
